Comparison of the pharmacodynamics and pharmacokinetics of bolus subcutaneous insulin glulisine and insulin lispro in obese patients with type 2 diabetes

被引：0

作者：

Luzio, SD ^{[1
]}

Peter, R ^{[1
]}

Dunseath, GJ ^{[1
]}

Mustafa, N ^{[1
]}

Owens, DR ^{[1
]}

机构：

[1] Llandough Hosp, Diabet Res Unit, Penarth, S Glam, Wales

来源：

DIABETOLOGIA | 2005年 / 48卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

844

引用

页码：A307 / A307

页数：1

共 50 条

[1] Pharmacodynamics and pharmacokinetics of insulin glulisine compared with insulin lispro and regular human insulin in patients with Type 2 diabetes
Kapitza, C
Becker, RHA
Frick, AD
Heise, T
Rave, K
[J]. DIABETOLOGIA, 2004, 47 : A265 - A265
[2] Pharmacodynamics (PD) and pharmacokinetics (PK) of insulin glulisine compared with insulin lispro (IL) and regular human insulin (RHI) in patients with type 2 diabetes
Becker, RHA
Frick, AD
Kapitza, C
Heise, T
Rave, K
[J]. DIABETES, 2004, 53 : A119 - A119
[3] Comparison of Pharmacokinetics and Pharmacodynamics of Inhaled Technosphere Insulin and Subcutaneous Insulin Lispro in the Treatment of Type 1 Diabetes Mellitus
Marshall Grant
Tim Heise
Robert Baughman
[J]. Clinical Pharmacokinetics, 2022, 61 : 413 - 422
[4] Comparison of Pharmacokinetics and Pharmacodynamics of Inhaled Technosphere Insulin and Subcutaneous Insulin Lispro in the Treatment of Type 1 Diabetes Mellitus
Grant, Marshall
Heise, Tim
Baughman, Robert
[J]. CLINICAL PHARMACOKINETICS, 2022, 61 (03) : 413 - 422
[5] Pharmacodynamics (PD) and pharmacokinetics (PK) of insulin glulisine (GLU) versus insulin lispro (IL) and regular human insulin (RHI) in patients with type 1 diabetes
Burger, F
Scholtz, H
Frick, A
Becker, RHA
[J]. DIABETES, 2004, 53 : A557 - A557
[6] Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes
Hompesch, Marcus
Ocheltree, Scott M.
Wondmagegnehu, Eshetu T.
Morrow, Linda A.
Kollmeier, Alexa P.
Campaigne, Barbara N.
Jacober, Scott J.
[J]. CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (11) : 2679 - 2687
[7] Comparison of the pharmacokinetics and pharmacodynamics of subcutaneous and inhaled insulin lispro in healthy pasted volunteers
McElduff, A
Farr, S
Ward, E
Okumu, F
Mather, L
Gonda, I
Rubsamen, R
Dimarchi, R
Wolff, R
[J]. DIABETES, 1998, 47 : A105 - A105
[8] Pharmacodynamics of insulin Lispro in 2 patients with type II diabetes mellitus
Jehle, PM
Fussganger, RD
Seibold, A
Luttke, B
Bohm, BO
[J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1996, 34 (11) : 498 - 503
[9] Efficacy and safety of insulin glulisine and insulin lispro combined with insulin glargine in patients with Type 1 diabetes
Prager, R
Dreyer, M
Robinson, A
Busch, K
Penfornis, A
Souhami, E
[J]. DIABETOLOGIA, 2004, 47 : A301 - A301
[10] Insulin Glulisine Compared to Insulin Aspart and to Insulin Lispro Administered by Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: A Randomized Controlled Trial
van Bon, Arianne C.
Bode, Bruce W.
Sert-Langeron, Caroline
DeVries, J. Hans
Charpentier, Guillaume
[J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2011, 13 (06) : 607 - 614

← 1 2 3 4 5 →